Latest T helper cell Stories

WORCESTER, Mass. and TORONTO, June 10, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced the results of the Company's annual meeting of stockholders held on June 8, 2011. (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) At the annual meeting of stockholders, the following directors were elected to serve on the Board of Directors until the next annual meeting of stockholders: John Barratt, Brian McGee, Nola Masterson,...

Study suggests new therapeutic targets for virally-induced asthma attacksWhen children with asthma get the flu, they often land in the hospital gasping for air. Researchers at Children's Hospital Boston have found a previously unknown biological pathway explaining why influenza induces asthma attacks. Studies in a mouse model, published online May 29 by the journal Nature Immunology, reveal that influenza activates a newly recognized group of immune cells called natural helper cells "“...

(Ivanhoe Newswire)"”Cells found naturally in the body may help prevent the rejection of an organ transplant. Research shows new cell therapy could also eliminate a transplant patient's need for life-long medication and could help their transplant last longer.Currently patients have to take immunosuppressant drugs to prevent a new organ from being rejected after transplant. Unfortunately, these drugs also suppress the immune system leaving the patient more susceptible to tumors and...

New cell therapy to prevent organ rejection could remove the need for life-long medication and boost the longevity of a transplant for patientsResearchers at King's College London have used cells found naturally in the body, to re-educate the immune system to prevent rejection of an organ transplant while remaining capable of fighting infections and cancer.Currently, patients must take immunosuppressant drugs to prevent a new organ from being rejected after transplantation. However, these...

A team of researchers "” led by Sang-Hun Lee, at Hanyang University, Republic of Korea, and Kwang-Soo Kim, at Harvard Medical School, Belmont, "” has now compared the ability of cells derived from different types of human stem cell to reverse disease in a rat model of Parkinson disease and identified a stem cell population that they believe could be clinically relevant.Parkinson disease results from the progressive loss of a specific subpopulation of nerve cells. Current treatments...

NEW YORK, May 9, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC:GNBT) announced that their May 5th RetailInvestorConferences.com presentation is available for on-demand viewing. LINK: www.retailinvestorconferences.com>Click the red "register/ watch event now" button. Generex'spresentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks. About Generex Biotechnology...

Researchers at the Stanford University School of Medicine have taken a machine already in use for the measurement of impurities in semiconductors and used it to analyze immune cells in far more detail than has been possible before. The new technology lets scientists take simultaneous measurements of dozens of features located on and in cells, whereas the existing technology typically begins to encounter technical limitations at about a half-dozen.The investigators were able not only to...

WORCESTER, Mass. and TORONTO, May 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced publication of results of studies applicable to the early diagnosis, and possibly treatment of, Type 1 diabetes. The study, entitled: "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes" appears in the April issue of the international peer-reviewed journal Hormone and Metabolism...

NEW YORK, May 2, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC: GNBT) today announced that Mark Fletcher, CEO, will present at RetailInvestorConferences.com. DATE: May 5th, 2011TIME: 11:00 AM EDTLINK: www.retailinvestorconferences.com>Click the red "register/ watch event now" button. This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's...

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model. Unlike other known cytokines, they write in the journal Nature Immunology, this messenger substance is essential for the development of the disease. By the end of this year, a clinical trial will be launched in which GM-CSF is to be neutralized in MS patients.The immune systems...